Endocrine therapy has proven its efficacy as a valuable adjuvant therapeutic tool in HR-positive BCs due to its ability to target the estrogen and/or progesterone receptors (ER and PR) in order to inhibit cancer growth [29]. Here, ESR1 is linked to cancer.